CN112057424B - Troxerutin freeze-dried powder injection and preparation method thereof - Google Patents
Troxerutin freeze-dried powder injection and preparation method thereof Download PDFInfo
- Publication number
- CN112057424B CN112057424B CN202010985828.2A CN202010985828A CN112057424B CN 112057424 B CN112057424 B CN 112057424B CN 202010985828 A CN202010985828 A CN 202010985828A CN 112057424 B CN112057424 B CN 112057424B
- Authority
- CN
- China
- Prior art keywords
- troxerutin
- freeze
- dried powder
- powder injection
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 title claims abstract description 55
- 229960003232 troxerutin Drugs 0.000 title claims abstract description 55
- 238000002347 injection Methods 0.000 title claims abstract description 37
- 239000007924 injection Substances 0.000 title claims abstract description 37
- 239000000843 powder Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 28
- 239000000243 solution Substances 0.000 claims abstract description 22
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 15
- 239000001509 sodium citrate Substances 0.000 claims abstract description 15
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 14
- 238000004108 freeze drying Methods 0.000 claims abstract description 13
- 238000001914 filtration Methods 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008215 water for injection Substances 0.000 claims abstract description 9
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- -1 hydroxyethyl rutin derivatives Chemical class 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- IYVFNTXFRYQLRP-VVSTWUKXSA-N 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4h-chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(OCCO)C=C3OC=2C=2C=C(OCCO)C(OCCO)=CC=2)=O)O1 IYVFNTXFRYQLRP-VVSTWUKXSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010985828.2A CN112057424B (en) | 2020-09-18 | 2020-09-18 | Troxerutin freeze-dried powder injection and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010985828.2A CN112057424B (en) | 2020-09-18 | 2020-09-18 | Troxerutin freeze-dried powder injection and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112057424A CN112057424A (en) | 2020-12-11 |
CN112057424B true CN112057424B (en) | 2022-09-16 |
Family
ID=73680748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010985828.2A Active CN112057424B (en) | 2020-09-18 | 2020-09-18 | Troxerutin freeze-dried powder injection and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112057424B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114569550A (en) * | 2022-03-08 | 2022-06-03 | 石家庄四药有限公司 | Troxerutin injection and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035933A1 (en) * | 1998-12-11 | 2000-06-22 | Laboratoires Negma | Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same |
CN1729989A (en) * | 2004-09-06 | 2006-02-08 | 成都百康医药工业药理毒理研究院 | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method |
WO2011034464A1 (en) * | 2009-09-15 | 2011-03-24 | Общество С Ограниченной Ответственностью "Герофарм" | Injectable dosage form for the treatment of an acute ischaemic insult and cranial trauma, manufacturing method and use |
CN102580055A (en) * | 2012-03-09 | 2012-07-18 | 张睿 | Troxerutin-cerebroprotein hydrolysate dripping pill and preparation method thereof |
CN105079015A (en) * | 2014-05-21 | 2015-11-25 | 蚌埠丰原涂山制药有限公司 | Troxerutin freeze-dried powder injection and preparation method thereof |
CN110339172A (en) * | 2019-07-02 | 2019-10-18 | 湖北美林药业有限公司 | Troxerutin for Injection and preparation method thereof |
-
2020
- 2020-09-18 CN CN202010985828.2A patent/CN112057424B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035933A1 (en) * | 1998-12-11 | 2000-06-22 | Laboratoires Negma | Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same |
CN1729989A (en) * | 2004-09-06 | 2006-02-08 | 成都百康医药工业药理毒理研究院 | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method |
WO2011034464A1 (en) * | 2009-09-15 | 2011-03-24 | Общество С Ограниченной Ответственностью "Герофарм" | Injectable dosage form for the treatment of an acute ischaemic insult and cranial trauma, manufacturing method and use |
CN102580055A (en) * | 2012-03-09 | 2012-07-18 | 张睿 | Troxerutin-cerebroprotein hydrolysate dripping pill and preparation method thereof |
CN105079015A (en) * | 2014-05-21 | 2015-11-25 | 蚌埠丰原涂山制药有限公司 | Troxerutin freeze-dried powder injection and preparation method thereof |
CN110339172A (en) * | 2019-07-02 | 2019-10-18 | 湖北美林药业有限公司 | Troxerutin for Injection and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
曲克芦丁注射液的稳定性研究;李勃,等;《北方药学》;20061231;第15-16页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112057424A (en) | 2020-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105434373B (en) | A kind of injection Oxiracetam lyophilized preparation and preparation method thereof | |
CN100506213C (en) | Lansoprazole freeze-dried powder for injection and preparing method thereof | |
CN112057424B (en) | Troxerutin freeze-dried powder injection and preparation method thereof | |
IE890854L (en) | Lyophilized pharmaceutical preparations | |
CN112007000A (en) | Espressole sodium freeze-dried powder injection and preparation method thereof | |
CN104095847B (en) | A kind of pharmaceutical composition that comprises Imipenem and Cilasatin Sodium and preparation thereof | |
RU1836079C (en) | Technique of production of lyophilizate | |
CN103768028A (en) | Esomeprazole sodium sterile lyophilized powder for injection and preparation process of lyophilized powder | |
CN112353799A (en) | Cimetidine composition for injection and preparation method and application thereof | |
CN104013585A (en) | Piracetam freeze-dried powder injection for injection and preparation method thereof | |
CN113081975B (en) | Preparation method of clindamycin phosphate freeze-dried powder injection for injection | |
CN101829065B (en) | Lansoprazole composition freeze-dried powder for injection | |
CN107714664A (en) | Aspirin-Al-lysine for injection freeze drying powder injection and preparation method thereof | |
JPH0374643B2 (en) | ||
CN114681409A (en) | Famotidine for injection and preparation method thereof | |
CN103830166B (en) | Preparation method of hypertonic resuscitation fluid and application thereof | |
CN110680807A (en) | Preparation method of propyl gallate for injection | |
CN113143868B (en) | Papaverine hydrochloride for injection and preparation method thereof | |
CN113230216B (en) | Piracetam freeze-dried powder injection for injection and preparation method thereof | |
CN114685581B (en) | Troxerutin for injection and preparation process thereof | |
CN108653216B (en) | Tigecycline for injection | |
CN113069420B (en) | Sodium ozagrel for injection and preparation method thereof | |
CN109172626B (en) | Wild chrysanthemum injection and preparation method thereof | |
CN107281121B (en) | (S) -4-hydroxy-2 oxo-1-pyrrolidine acetamide freeze-dried powder for injection and preparation method thereof | |
CN116036030A (en) | Omeprazole sodium freeze-dried powder injection for injection and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 475000 66 south section of Jinming Road, Kaifeng, Henan Patentee after: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Patentee after: Hefei Kangnuo Biopharmaceutical Co.,Ltd. Address before: 475000 66 south section of Jinming Road, Kaifeng, Henan Patentee before: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Patentee before: Hefei Kangnuo biopharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 475000 66 south section of Jinming Road, Kaifeng, Henan Patentee after: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Patentee after: Kangnuo Biopharmaceutical Co.,Ltd. Address before: 475000 66 south section of Jinming Road, Kaifeng, Henan Patentee before: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Patentee before: Hefei Kangnuo Biopharmaceutical Co.,Ltd. |